Related Experiment Videos
Pemetrexed in pancreatic cancer
Jean-François Seitz1, Laetitia Dahan, Pauline Ries
1C.H.U. la Timone and Université de la Méditerranée Marseille, France. jseitz@mail.ap-hm.fr
Oncology (Williston Park, N.Y.)
|January 20, 2005
Summary
Adding pemetrexed to gemcitabine chemotherapy for advanced pancreatic cancer did not improve overall survival in a phase III trial. While response rates and progression-free survival showed some benefit, survival outcomes remained similar between treatment arms.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Trials
Background:
- Gemcitabine is the standard chemotherapy for advanced pancreatic cancer.
- Few combination therapies have demonstrated superior survival over gemcitabine monotherapy.
- Pemetrexed shows in vitro synergy with gemcitabine and has demonstrated activity in pancreatic cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of a combination regimen of gemcitabine and pemetrexed compared to gemcitabine alone in patients with advanced pancreatic cancer.
- To assess overall survival, response rate, progression-free survival, and quality of life.
Main Methods:
- A phase III clinical trial comparing gemcitabine monotherapy to a combination of gemcitabine and pemetrexed with vitamin supplementation.
- Patients with advanced pancreatic cancer were randomized to receive either treatment arm.
- Primary endpoint was overall survival; secondary endpoints included response rate, progression-free survival, and quality of life.
Main Results:
- The combination of gemcitabine and pemetrexed showed an increase in response rate and time to progression compared to gemcitabine alone.
- However, there were no statistically significant differences in overall survival between the two treatment arms.
- Neutropenia was a significant toxicity observed in the combination arm.
Conclusions:
- The combination of gemcitabine and pemetrexed does not offer a significant survival benefit over gemcitabine monotherapy for advanced pancreatic cancer.
- While the combination may improve response rates and delay progression, its clinical utility is limited by the lack of overall survival improvement and notable toxicity.